Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.

Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6^th hosted at the Lotte New York Palace in New York, NY.

Additionally, on March 3^rd at 10:30 AM ET, Dr. Wagner will be presenting at the TD Cowen 45^th Annual Healthcare Conference hosted at the Boston Marriott Copley Place in Boston, MA.

About Forte

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Source: Forte Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250203279326/en/

LifeSci Advisors

Mike Moyer, Managing Director

mmoyer@lifesciadvisors.com